■我们的疾病成本研究旨在提供墨西哥背景下与系统性红斑狼疮(SLE)相关的负担的估计。
■我们的模型用于模拟墨西哥SLE患者在5年内的资源利用和经济后果。该模型模拟了四种健康状况-SLE的三种表型,包括轻度,中度,和严重的国家,和死亡。从文献中检索临床参数。我们模型中的资源利用代表了墨西哥医疗保健系统中最常见的做法。这些包括疾病管理,短暂性事件(例如感染,耀斑,和SLE相关器官损伤引起的并发症),和间接成本。没有考虑直接的非医疗费用。进行单向敏感性分析。
■目标墨西哥SLE患者人数为57,754。诊断为轻度的SLE患者的数量,中度,和严重表型分别为8,230,44,291和5,233。疾病管理成本,包括每个表型的治疗和疾病随访,40亿MXN(4.15亿美元);短暂性事件的成本(感染,耀斑,与SLE相关的器官损害的后果)为MXN50亿(4.78亿美元)。成年墨西哥SLE患者的生产力损失成本估计为170亿MXN(16亿美元)。从付款人和社会角度来看,墨西哥5年的SLE总成本估计为90亿MXN(8.93亿美元)和260亿Mon(25亿美元)。分别。超过5年,从付款人和社会角度来看,每名患者每年的费用分别为32,131MXN(3,095美元)和91,661MXN(8,830美元),分别。
■研究结果指出了与SLE相关的巨大经济负担,包括疾病进展和SLE短暂事件的费用,比如爆发,感染,和器官损伤,除了工作能力受损导致的生产率损失之外。
UNASSIGNED: Our cost of illness study aimed to provide an estimate of the burden related to systemic lupus erythematosus (SLE) in the Mexican context.
UNASSIGNED: Our model was used to simulate the resource utilization and economic consequences over a period of 5 years for patients with SLE in Mexico. The model simulated four health states-three phenotypes of SLE, including mild, moderate, and severe states, and death. Clinical parameters were retrieved from the literature. Resource utilization in our model represents the most common practice in the Mexican healthcare system. These include disease management, transient events (e.g. infections, flares, and complications due to SLE-related organ damage), and indirect costs. Direct non-medical costs were not considered. One-way sensitivity analysis was performed.
UNASSIGNED: The number of targeted Mexican SLE patients was 57,754. The numbers of SLE patients diagnosed with mild, moderate, and severe phenotypes were 8,230, 44,291, and 5,233, respectively. Disease management costs, including the treatment of each phenotype and disease follow-up, were MXN 4 billion ($ 415 million); the costs of transient events (infections, flares, and consequences of SLE-related organ damage) were MXN 5 billion ($ 478 million). Productivity loss costs among adult employed Mexican patients with SLE were estimated at MXN 17 billion ($ 1.6 billion). The total SLE cost in Mexico over 5 years from the payer and societal perspectives is estimated at MXN 9 billion ($ 893 million) and 26 billion ($ 2.5 billion), respectively. Over 5 years, the costs per patient per year from the payer and societal perspectives were MXN 32,131($ 3,095) and MXN 91,661($ 8,830), respectively.
UNASSIGNED: The findings pointed out the substantial economic burden associated with SLE, including the costs of disease progression and SLE transient events, such as flare-ups, infections, and organ damage, in addition to productivity loss due to work capacity impairment.